medigraphic.com
ISSN 2500-7106 (Electronic)
ISSN 0123-2576 (Print)
Medicina & Laboratorio

2022, Number 1

<< Back Next >>

Medicina & Laboratorio 2022; 26 (1)

Metabolic syndrome: a literature review

Fragozo-Ramos MC

Language: Spanish
References: 89
Page: 47-62
PDF size: 253.46 Kb.


ABSTRACT

Metabolic syndrome is a clinical condition that includes a group of cardiometabolic abnormalities such as hypertension, central obesity, insulin resistance, and atherogenic dyslipidemia. The prevalence of metabolic syndrome has increased in recent years in the world, representing a public health problem because it directly increases between two and six times the risk of cardiovascular diseases and type 2 diabetes mellitus. Lifestyle changes can reverse the components of metabolic syndrome, but pharmacological intervention is sometimes necessary for tighter control of risk factors. This article aims to explain clearly and precisely the general aspects of metabolic syndrome in adults.


REFERENCES

  1. Lorenzo C, Williams K, Hunt KJ, Haffner SM.The National Cholesterol Education Program -Adult Treatment Panel III, International DiabetesFederation, and World Health Organizationdefinitions of the metabolic syndrome as predictorsof incident cardiovascular disease anddiabetes. Diabetes Care 2007;30:8-13. https://doi.org/10.2337/dc06-1414.

  2. Alberti KG, Eckel RH, Grundy SM, Zimmet PZ,Cleeman JI, Donato KA, et al. Harmonizingthe metabolic syndrome: a joint interim statementof the International Diabetes FederationTask Force on Epidemiology and Prevention;National Heart, Lung, and Blood Institute; AmericanHeart Association; World Heart Federation;International Atherosclerosis Society; andInternational Association for the Study of Obesity.Circulation 2009;120:1640-1645. https://doi.org/10.1161/circulationaha.109.192644.

  3. Mottillo S, Filion KB, Genest J, Joseph L,Pilote L, Poirier P, et al. The metabolic syndromeand cardiovascular risk a systematicreview and meta-analysis. J Am Coll Cardiol2010;56:1113-1132. https://doi.org/10.1016/j.jacc.2010.05.034.

  4. McNeill AM, Rosamond WD, Girman CJ,Golden SH, Schmidt MI, East HE, et al. Themetabolic syndrome and 11-year risk of incidentcardiovascular disease in the atherosclerosisrisk in communities study. Diabetes Care2005;28:385-390. https://doi.org/10.2337/diacare.28.2.385.

  5. Meigs JB, Rutter MK, Sullivan LM, Fox CS,D'Agostino RB, Sr., Wilson PW. Impact of insulinresistance on risk of type 2 diabetes andcardiovascular disease in people with metabolicsyndrome. Diabetes Care 2007;30:1219-1225. https://doi.org/10.2337/dc06-2484.

  6. Suárez-Ortegón MF, Arbeláez A, MosqueraM, Méndez F, Pradilla A, Aguilar-de Plata C.Association of self-reported familial history ofcardiometabolic disease with metabolic syndromein apparently healthy urban Colombianmen. Am J Hum Biol 2013;25:228-230. https://doi.org/10.1002/ajhb.22371.

  7. Ozcan U, Cao Q, Yilmaz E, Lee AH, IwakoshiNN, Ozdelen E, et al. Endoplasmic reticulumstress links obesity, insulin action, and type 2diabetes. Science 2004;306:457-461. https://doi.org/10.1126/science.1103160.

  8. Duvnjak L, Duvnjak M. The metabolic syndrome- an ongoing story. J Physiol Pharmacol2009;60:S19-24.

  9. Meshkani R, Adeli K. Hepatic insulin resistance,metabolic syndrome and cardiovascular disease.Clin Biochem 2009;42:1331-1346. https://doi.org/10.1016/j.clinbiochem.2009.05.018.

  10. Sookoian S, Pirola CJ. Metabolic syndrome:from the genetics to the pathophysiology. CurrHypertens Rep 2011;13:149-157. https://doi.org/10.1007/s11906-010-0164-9.

  11. Reaven G. Metabolic syndrome: pathophysiologyand implications for managementof cardiovascular disease. Circulation2002;106:286-288. https://doi.org/10.1161/01.cir.0000019884.36724.d9.

  12. Sears B, Perry M. The role of fatty acids in insulinresistance. Lipids Health Dis 2015;14:121.https://doi.org/10.1186/s12944-015-0123-1.

  13. Grundy SM. Adipose tissue and metabolicsyndrome: too much, too little or neither. EurJ Clin Invest 2015;45:1209-1217. https://doi.org/10.1111/eci.12519.

  14. Boden G. Obesity and free fatty acids. EndocrinolMetab Clin North Am 2008;37:635-646.https://doi.org/10.1016/j.ecl.2008.06.007.

  15. Lafontan M. Adipose tissue and adipocytedysregulation. Diabetes Metab 2014;40:16-28.https://doi.org/10.1016/j.diabet.2013.08.002.

  16. Grundy SM. Metabolic syndrome pandemic.Arterioscler Thromb Vasc Biol 2008;28:629-636.https://doi.org/10.1161/atvbaha.107.151092.

  17. Czech MP. Mechanisms of insulin resistancerelated to white, beige, and brown adipocytes.Mol Metab 2020;34:27-42. https://doi.org/10.1016/j.molmet.2019.12.014.

  18. Aguilar M, Bhuket T, Torres S, Liu B, WongRJ. Prevalence of the metabolic syndromein the United States, 2003-2012. Jama2015;313:1973-1974. https://doi.org/10.1001/jama.2015.4260.

  19. Ford ES, Giles WH, Mokdad AH. Increasingprevalence of the metabolic syndrome amongU.S. Adults. Diabetes Care 2004;27:2444-2449.https://doi.org/10.2337/diacare.27.10.2444.

  20. Hirode G, Wong RJ. Trends in the prevalenceof metabolic syndrome in the United States,2011-2016. JAMA 2020;323:2526-2528.https://doi.org/10.1001/jama.2020.4501.

  21. Márquez-Sandoval F, Macedo-Ojeda G,Viramontes-Hörner D, Fernández-BallartJD, Salas-Salvadó J, Vizmanos B. The prevalenceof metabolic syndrome in Latin America:a systematic review. Public Health Nutr2011;14:1702-1713. https://doi.org/10.1017/s1368980010003320.

  22. Ramírez-Vélez R, Correa-Bautista JE, Sanders-Tordecilla A, Ojeda-Pardo ML, Cobo-Mejía EA, Castellanos-Vega RD, et al. Percentageof body fat and fat mass index as ascreening tool for metabolic syndrome predictionin Colombian university students. Nutrients2017;9:1009. https://doi.org/10.3390/nu9091009.

  23. Davila EP, Quintero MA, Orrego ML, Ford ES,Walke H, Arenas MM, et al. Prevalence andrisk factors for metabolic syndrome in Medellinand surrounding municipalities, Colombia,2008-2010. Prev Med 2013;56:30-34. https://doi.org/10.1016/j.ypmed.2012.10.027.

  24. Higuita-Gutiérrez LF, Martínez-Quiroz WJ,Cardona-Arias JA. Prevalence of metabolicsyndrome and its association with sociodemographiccharacteristics in participants ofa public chronic disease control program inMedellin, Colombia, in 2018. Diabetes MetabSyndr Obes 2020;13:1161-1169. https://doi.org/10.2147/dmso.S242826.

  25. Mann JP, Savage DB. What lipodystrophiesteach us about the metabolic syndrome. JClin Invest 2019;129:4009-4021. https://doi.org/10.1172/jci129190.

  26. Fox CS, Massaro JM, Hoffmann U, Pou KM,Maurovich-Horvat P, Liu CY, et al. Abdominalvisceral and subcutaneous adipose tissuecompartments: association with metabolicrisk factors in the Framingham Heart Study.Circulation 2007;116:39-48. https://doi.org/10.1161/circulationaha.106.675355.

  27. Suiter C, Singha SK, Khalili R, Shariat-MadarZ. Free fatty acids: Circulating contributorsof metabolic syndrome. Cardiovasc HematolAgents Med Chem 2018;16:20-34. https://doi.org/10.2174/1871525716666180528100002.

  28. Žák A, Burda M, Vecka M, Zeman M, TvrzickáE, Staňková B. Fatty acid composition indicatestwo types of metabolic syndrome independentof clinical and laboratory parameters.Physiol Res 2014;63:S375-385. https://doi.org/10.33549/physiolres.932868.

  29. Dai L, Gonçalves CM, Lin Z, Huang J, LuH, Yi L, et al. Exploring metabolic syndromeserum free fatty acid profiles based onGC-SIM-MS combined with random forestsand canonical correlation analysis. Talanta2015;135:108-114. https://doi.org/10.1016/j.talanta.2014.12.039.

  30. Fathi-Dizaji B. The investigations of geneticdeterminants of the metabolic syndrome. Diabetes Metab Syndr 2018;12:783-789. https://doi.org/10.1016/j.dsx.2018.04.009.

  31. Carson C, Lawson HA. Epigenetics of metabolicsyndrome. Physiol Genomics 2018;50:947-955. https://doi.org/10.1152/physiolgenomics.00072.2018.

  32. Kuneš J, Vaněčková I, Mikulášková B, BehuliakM, Maletínská L, Zicha J. Epigenetics anda new look on metabolic syndrome. Physiol Res2015;64:611-620. https://doi.org/10.33549/physiolres.933174.

  33. Takahara M, Shimomura I. Metabolic syndromeand lifestyle modification. Rev EndocrMetab Disord 2014;15:317-327. https://doi.org/10.1007/s11154-014-9294-8.

  34. Kolovou GD, Anagnostopoulou KK, CokkinosDV. Pathophysiology of dyslipidaemiain the metabolic syndrome. Postgrad Med J2005;81:358-366. https://doi.org/10.1136/pgmj.2004.025601.

  35. Iqbal J, Al Qarni A, Hawwari A, Alghanem AF,Ahmed G. Metabolic syndrome, dyslipidemiaand regulation of lipoprotein metabolism. CurrDiabetes Rev 2018;14:427-433. https://doi.org/10.2174/1573399813666170705161039.

  36. Rochlani Y, Pothineni NV, KovelamudiS, Mehta JL. Metabolic syndrome: pathophysiology,management, and modulationby natural compounds. Ther Adv CardiovascDis 2017;11:215-225. https://doi.org/10.1177/1753944717711379.

  37. Turpin SM, Ryall JG, Southgate R, DarbyI, Hevener AL, Febbraio MA, et al.Examination of 'lipotoxicity' in skeletalmuscle of high-fat fed and ob/ob mice. JPhysiol 2009;587:1593-1605. https://doi.org/10.1113/jphysiol.2008.166033.

  38. Adams JM, Pratipanawatr T, Berria R, WangE, DeFronzo RA, Sullards MC, et al. Ceramidecontent is increased in skeletal musclefrom obese insulin-resistant humans. Diabetes2004;53:25-31. https://doi.org/10.2337/diabetes.53.1.25.

  39. Perry RJ, Camporez JG, Kursawe R, TitchenellPM, Zhang D, Perry CJ, et al. Hepaticacetyl CoA links adipose tissue inflammationto hepatic insulin resistance and type 2 diabetes.Cell 2015;160:745-758. https://doi.org/10.1016/j.cell.2015.01.012.

  40. Neuhauser HK. The metabolic syndrome.Lancet 2005;366:1922-1924. https://doi.org/10.1016/s0140-6736(05)67780-x.

  41. Aschner P, Buendía R, Brajkovich I, GonzalezA, Figueredo R, Juarez XE, et al. Determinationof the cutoff point for waist circumferencethat establishes the presence of abdominalobesity in Latin American men and women.Diabetes Res Clin Pract 2011;93:243-247.https://doi.org/10.1016/j.diabres.2011.05.002.

  42. Prado CM, Siervo M, Mire E, Heymsfield SB,Stephan BC, Broyles S, et al. A population-basedapproach to define body-composition phenotypes.Am J Clin Nutr 2014;99:1369-1377.https://doi.org/10.3945/ajcn.113.078576.

  43. Shea JL, King MT, Yi Y, Gulliver W, Sun G.Body fat percentage is associated with cardiometabolicdysregulation in BMI-defined normalweight subjects. Nutr Metab Cardiovasc Dis2012;22:741-747. https://doi.org/10.1016/j.numecd.2010.11.009.

  44. Yusuf S, Joseph P, Rangarajan S, Islam S,Mente A, Hystad P, et al. Modifiable risk factors,cardiovascular disease, and mortalityin 155 722 individuals from 21 high-income,middle-income, and low-income countries(PURE): a prospective cohort study. Lancet2020;395:795-808. https://doi.org/10.1016/s0140-6736(19)32008-2.

  45. Mancia G, Bousquet P, Elghozi JL, EslerM, Grassi G, Julius S, et al. The sympatheticnervous system and the metabolic syndrome.J Hypertens 2007;25:909-920. https://doi.org/10.1097/HJH.0b013e328048d004.

  46. Drager LF, Togeiro SM, Polotsky VY, Lorenzi-Filho G. Obstructive sleep apnea: a cardiometabolicrisk in obesity and the metabolicsyndrome. J Am Coll Cardiol 2013;62:569-576.https://doi.org/10.1016/j.jacc.2013.05.045.

  47. Qiao Q, Gao W, Zhang L, Nyamdorj R, TuomilehtoJ. Metabolic syndrome and cardiovasculardisease. Ann Clin Biochem 2007;44:232-263.https://doi.org/10.1258/000456307780480963.

  48. Cuspidi C, Meani S, Fusi V, Severgnini B, ValerioC, Catini E, et al. Metabolic syndromeand target organ damage in untreated essentialhypertensives. J Hypertens 2004;22:1991-1998. https://doi.org/10.1097/00004872-200410000-00023.

  49. Zhao F, Yang R, Maimaitiaili R, Tang J, ZhaoS, Xiong J, et al. Cardiac, macro-, and microcirculatoryabnormalities in association withindividual metabolic syndrome component:The northern shanghai study. Front CardiovascMed 2021;8:690521. https://doi.org/10.3389/fcvm.2021.690521.

  50. Park JH, Kim BS, Ovbiagele B. Concomitantdiabetes or hypertension with metabolic syndromeon the extent of intracranial atheroscleroticstenosis. Neurol Sci 2020;41:387-395.https://doi.org/10.1007/s10072-019-04105-w.

  51. Xie K, Bao L, Jiang X, Ye Z, Bing J, Dong Y, et al.The association of metabolic syndrome componentsand chronic kidney disease in patients withhypertension. Lipids Health Dis 2019;18:229.https://doi.org/10.1186/s12944-019-1121-5.

  52. Batista TM, Haider N, Kahn CR. Defining theunderlying defect in insulin action in type 2 diabetes.Diabetologia 2021;64:994-1006. https://doi.org/10.1007/s00125-021-05415-5.

  53. López-Jaramillo P, Calderón C, Castillo J, EscobarID, Melgarejo E, Parra GA. Prediabetesin Colombia: Expert consensus. Colomb Med2017;48:191-203. https://doi.org/10.25100/cm.v43i4.3662.

  54. Halban PA, Polonsky KS, Bowden DW, HawkinsMA, Ling C, Mather KJ, et al. β-cell failurein type 2 diabetes: postulated mechanisms andprospects for prevention and treatment. J ClinEndocrinol Metab 2014;99:1983-1992. https://doi.org/10.1210/jc.2014-1425.

  55. American Diabetes Association (ADA).2. Classification and diagnosis of diabetes:Standards of medical care in diabetes-2021.Diabetes Care 2021;44:S15-33. https://doi.org/10.2337/dc21-S002.

  56. Bi X, Yeo PL, Loo YT, Henry CJ. Associationsbetween circulating fatty acid levels and metabolicrisk factors. J Nutr Intermed Metab2019;15:65-69. https://doi.org/10.1016/j.jnim.2019.02.002.

  57. Lu Y, Wang Y, Ong CN, Subramaniam T, ChoiHW, Yuan JM, et al. Metabolic signaturesand risk of type 2 diabetes in a Chinese population:an untargeted metabolomics studyusing both LC-MS and GC-MS. Diabetologia2016;59:2349-2359. https://doi.org/10.1007/s00125-016-4069-2.

  58. Sanchez-Garrido MA, Tena-Sempere M. Metabolicdysfunction in polycystic ovary syndrome:Pathogenic role of androgen excess andpotential therapeutic strategies. Mol Metab2020;35:100937. https://doi.org/10.1016/j.molmet.2020.01.001.

  59. Yilmaz B, Vellanki P, Ata B, Yildiz BO. Metabolicsyndrome, hypertension, and hyperlipidemiain mothers, fathers, sisters, and brothers ofwomen with polycystic ovary syndrome: a systematicreview and meta-analysis. Fertil Steril2018;109:356-364. https://doi.org/10.1016/j.fertnstert.2017.10.018.

  60. Kazemi M, Pierson RA, Lujan ME, ChilibeckPD, McBreairty LE, Gordon JJ, et al.Comprehensive evaluation of type 2 diabetesand cardiovascular disease risk profiles inreproductive-age women with polycystic ovarysyndrome: A large Canadian cohort. J ObstetGynaecol Can 2019;41:1453-1460. https://doi.org/10.1016/j.jogc.2018.11.026.

  61. Meyer ML, Sotres-Alvarez D, Steiner AZ,Cousins L, Talavera GA, Cai J, et al. Polycysticovary syndrome signs and metabolic syndromein premenopausal Hispanic/Latina women:The HCHS/SOL study. J Clin Endocrinol Metab2020;105:e447-456. https://doi.org/10.1210/clinem/dgaa012.

  62. Neuschwander-Tetri BA. Non-alcoholic fatty liverdisease. BMC Med 2017;15:45. https://doi.org/10.1186/s12916-017-0806-8.

  63. Castro-Martínez MG, Banderas-Lares DZ,Ramírez-Martínez JC, Escobedo-de la PeñaJ. Prevalence of nonalcoholic fatty liver diseasein subjects with metabolic syndrome. Cir Cir2012;80:128-133.

  64. Caballería L, Pera G, Rodríguez L, AuladellMA, Bernad J, Canut S, et al. Metabolic syndromeand nonalcoholic fatty liver disease in aSpanish population: influence of the diagnosticcriteria used. Eur J Gastroenterol Hepatol2012;24:1007-1011. https://doi.org/10.1097/MEG.0b013e328355b87f.

  65. Kwon YM, Oh SW, Hwang SS, Lee C, Kwon H,Chung GE. Association of nonalcoholic fatty liverdisease with components of metabolic syndromeaccording to body mass index in Koreanadults. Am J Gastroenterol 2012;107:1852-1858. https://doi.org/10.1038/ajg.2012.314.

  66. Swarup S, Goyal A, Grigorova Y, et al. MetabolicSyndrome. StatPearls. Treasure Island(FL): StatPearls Publishing; 2021. Acceso 12 deagosto de 2021. Disponible en https://www.ncbi.nlm.nih.gov/books/NBK459248/.

  67. Alberti KG, Zimmet PZ. Definition, diagnosisand classification of diabetes mellitusand its complications. Part 1: diagnosis andclassification of diabetes mellitus provisionalreport of a WHO consultation. Diabet Med1998;15:539-553. https://doi.org/10.1002/(sici)1096-9136(199807)15:7<539::Aiddia668>3.0.Co;2-s.

  68. Expert Panel on Detection, Evaluation, andTreatment of High Blood Cholesterol inAdults. Executive summary of the third reportof The National Cholesterol Education Program(NCEP) Expert Panel on Detection, Evaluation,and Treatment of High Blood Cholesterolin Adults (Adult Treatment Panel III). JAMA2001;285:2486-2497. https://doi.org/10.1001/jama.285.19.2486.

  69. Balkau B, Charles MA. Comment on the provisionalreport from the WHO consultation. EuropeanGroup for the Study of Insulin Resistance(EGIR). Diabet Med 1999;16:442-443. https://doi.org/10.1046/j.1464-5491.1999.00059.x.

  70. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome--a new world-wide definition. A ConsensusStatement from the International Diabetes Federation.Diabet Med 2006;23:469-480. https://doi.org/10.1111/j.1464-5491.2006.01858.x.

  71. Einhorn D, Reaven GM, Cobin RH, Ford E,Ganda OP, Handelsman Y, et al. American Collegeof Endocrinology position statement onthe insulin resistance syndrome. Endocr Pract2003;9:237-252.

  72. Ruiz ÁJ, Aschner PJ, Puerta MF, CristanchoRA. Estudio IDEA (International Day for Evaluationof Abdominal Obesity): prevalencia deobesidad abdominal y factores de riesgo asociadosen atención primaria en Colombia. Biomédica2012;32:610-616.

  73. Gil JC, De Loredo L , Ramos DO, Lúquez H,Piña C, Bruce HG. Consenso Latinoamericanode la Asociación Latinoamericana de Diabetes(ALAD). Epidemiología, diagnóstico, control,prevención y tratamiento del síndrome metabólicoen adultos. Rev ALAD 2010;18:25-44.

  74. Sattar N, McConnachie A, Shaper AG, BlauwGJ, Buckley BM, de Craen AJ, et al. Canmetabolic syndrome usefully predict cardiovasculardisease and diabetes? Outcomedata from two prospective studies. Lancet2008;371:1927-1935. https://doi.org/10.1016/s0140-6736(08)60602-9.

  75. Ford ES, Li C, Sattar N. Metabolic syndromeand incident diabetes: current state of theevidence. Diabetes Care 2008;31:1898-1904.https://doi.org/10.2337/dc08-0423.

  76. Deen D. Metabolic syndrome: time for action.Am Fam Physician 2004;69:2875-2882.

  77. Saklayen MG. The global epidemic of themetabolic syndrome. Curr Hypertens Rep2018;20:12. https://doi.org/10.1007/s11906-018-0812-z.

  78. Grundy SM, Hansen B, Smith SC, Jr., CleemanJI, Kahn RA. Clinical management ofmetabolic syndrome: report of the AmericanHeart Association/National Heart, Lung, andBlood Institute/American Diabetes Associationconference on scientific issues related tomanagement. Arterioscler Thromb Vasc Biol2004;24:e19-24. https://doi.org/10.1161/01.Atv.0000112379.88385.67.

  79. Ryan NM, O'Donovan CB, Forster H, WoolheadC, Walsh MC. New tools for personalisednutrition: The Food4Me project. Nutr Bull2015;40:134-139. https://doi.org/https://doi.org/10.1111/nbu.12143.

  80. Masquio DC, de Piano-Ganen A, Oyama LM,Campos RM, Santamarina AB, de Souza GI,et al. The role of free fatty acids in the inflammatoryand cardiometabolic profile in adolescentswith metabolic syndrome engagedin interdisciplinary therapy. J Nutr Biochem2016;33:136-144. https://doi.org/10.1016/j.jnutbio.2016.03.017.

  81. Guerendiain M, Montes R, López-BelmonteG, Martín-Matillas M, Castellote AI, Martín-Bautista E, et al. Changes in plasma fatty acidcomposition are associated with improvementsin obesity and related metabolic disorders: Atherapeutic approach to overweight adolescents.Clin Nutr 2018;37:149-156. https://doi.org/10.1016/j.clnu.2016.11.006.

  82. Martin KA, Mani MV, Mani A. New targetsto treat obesity and the metabolic syndrome.Eur J Pharmacol 2015;763:64-74. https://doi.org/10.1016/j.ejphar.2015.03.093.

  83. Yanovski SZ, Yanovski JA. Long-term drugtreatment for obesity: a systematic and clinicalreview. Jama 2014;311:74-86. https://doi.org/10.1001/jama.2013.281361.

  84. Pi-Sunyer X, Astrup A, Fujioka K, GreenwayF, Halpern A, Krempf M, et al. A Randomized,controlled trial of 3.0 mg of liraglutide in weightmanagement. N Engl J Med 2015;373:11-22.https://doi.org/10.1056/NEJMoa1411892.

  85. Wilding JPH, Batterham RL, Calanna S, DaviesM, Van Gaal LF, Lingvay I, et al. Onceweeklysemaglutide in adults with overweightor obesity. N Engl J Med 2021;384:989. https://doi.org/10.1056/NEJMoa2032183.

  86. Lundgren JR, Janus C, Jensen SBK, Juhl CR,Olsen LM, Christensen RM, et al. Healthyweight loss maintenance with exercise, liraglutide,or both combined. N Engl J Med2021;384:1719-1730. https://doi.org/10.1056/NEJMoa2028198.

  87. Dalle-Grave R, Sartirana M, Calugi S. Personalizedcognitive-behavioural therapy for obesity(CBT-OB): theory, strategies and procedures.Biopsychosoc Med 2020;14:5. https://doi.org/10.1186/s13030-020-00177-9.

  88. Demirbas N, Kutlu R, Kurnaz A. The relationshipbetween mindful eating and body massindex and body compositions in adults. AnnNutr Metab 2021:77:262-270. https://doi.org/10.1159/000518675.

  89. Grundy SM. Metabolic syndrome update.Trends Cardiovasc Med 2016;26:364-373.https://doi.org/10.1016/j.tcm.2015.10.004.




2020     |     www.medigraphic.com